SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02504346

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Phase II, single-arm study to assess the safety and efficacy of AZD9291 (80 mg, orally, once daily) in second-line (or later) patients with EGFR mutation-positive, locally advanced or metastatic NSCLC, who have progressed following treatment with an approved epidermal growth factor tyrosine kinase inhibitor agent.

NCT02504346 Lung Cancer Targeted Therapy
MeSH:Lung Neoplasms
HPO:Neoplasm of the lung

1 Interventions

Name: AZD9291

Type: Drug
Group Labels: 1


Primary Outcomes

Description: Measured by RECIST 1.1

Measure: Objective response rate

Time: 12 weeks

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 T790M

4. Radiological disease progression following at least one prior EGFR TKI. 5. Documented EGFR mutation known to be associated with EGFR TKI sensitivity (also including T790M). --- T790M ---

HPO Nodes